FLUTICATONE VILO 200

Description

FLUTICATONE VILO 200 is a combination powder for inhalation containing Fluticasone Furoate 200 mcg and Vilanterol 25 mcg. This fixed-dose formulation is designed for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). By combining a corticosteroid (Fluticasone Furoate) and a long-acting beta2-agonist (Vilanterol), FLUTICATONE VILO 200 provides dual action—reducing inflammation in the airways and improving airflow to the lungs. It is administered via a dry powder inhaler, making it convenient and effective for daily respiratory management. What is Fluticasone Furoate and Vilanterol Powder for Inhalation? Fluticasone Furoate and Vilanterol powder for inhalation is a combination medication used in the management of asthma and COPD. Fluticasone Furoate 200 mcg is an inhaled corticosteroid that helps control inflammation and reduce airway swelling. Vilanterol 25 mcg is a long-acting beta2-agonist (LABA) that helps to relax airway muscles and improve breathing over a 24-hour period. Together, they work synergistically to prevent wheezing, shortness of breath, and exacerbation of chronic respiratory conditions. Uses of Fluticasone Furoate and Vilanterol Powder for Inhalation Maintenance treatment of asthma in adults and adolescents where the use of combination therapy is appropriate. Long-term treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Helps reduce the number of exacerbations in patients with a history of frequent flare-ups. Improves lung function and quality of life in patients with persistent respiratory symptoms. Fluticasone Furoate and Vilanterol Powder for Inhalation Side Effects As with all inhaled medications, side effects may vary from person to person. Common and less common side effects include: Common side effects: Throat irritation Cough Hoarseness or voice changes Headache Nasal congestion Oral candidiasis (thrush) Serious but rare side effects: Paradoxical bronchospasm (sudden worsening of breathing) Allergic reactions such as rash, swelling, or breathing difficulty Changes in heart rate or blood pressure Increased risk of pneumonia in COPD patients Rinsing the mouth after each use can help prevent oral thrush. Precautions Before Using FLUTICATONE VILO 200 Do not use FLUTICATONE VILO 200 for acute bronchospasm or asthma attacks. It is not a rescue inhaler. Inform your doctor if you have a history of tuberculosis, glaucoma, cataracts, osteoporosis, or any immune disorders. Use with caution in patients with cardiovascular disease, diabetes, or seizure disorders. Avoid abrupt discontinuation. The dose should be tapered under medical supervision when stopping the medicine. Not recommended for children under the age of 12 unless prescribed by a physician. Drug Interactions: What Drugs Interact with FLUTICATONE VILO 200? Several medications may interact with fluticasone furoate and vilanterol powder for inhalation, including: Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): May increase systemic steroid exposure and side effects. Beta-blockers (e.g., propranolol): May reduce the effectiveness of vilanterol and increase the risk of bronchospasm. Diuretics: May enhance the risk of hypokalemia when combined with LABAs like vilanterol. Other long-acting beta-agonists or corticosteroids: May increase the risk of side effects and should be avoided unless supervised. Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: May enhance the cardiovascular effects of vilanterol. Always inform your healthcare provider about all medications you are currently using to avoid harmful interactions. Conclusion FLUTICATONE VILO 200 offers a powerful, once-daily solution for managing chronic asthma and COPD symptoms. With Fluticasone Furoate 200 mcg and Vilanterol 25 mcg, it delivers reliable control over inflammation and bronchial constriction. Used consistently and correctly, it can significantly improve lung function and quality of life while reducing the risk of severe flare-ups.